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ORIGINAL ARTICLE
Clinical Validation of a Dried Blood Spot Assay for 8
Antihypertensive Drugs and 4 Active Metabolites
Laura E. J. Peeters, MSc,*† Lida Feyz, MD,‡ Edon Hameli, BSc,† Tom Zwart, BSc,†
Soma Bahmany, BSc,* Joost Daemen, MD, PhD,‡ Teun van Gelder, MD, PhD,*†
Jorie Versmissen, MD, PhD,† and Birgit C. P. Koch, PharmD, PhD*
Background: Drug nonadherence is one of the major challenges
faced by resistant hypertension patients, and identification of this
problem is needed for optimizing pharmacotherapy. Dried blood
spot (DBS) sampling is a minimally invasive method designed to
detect and determine the degree of nonadherence. In this study,
a DBS method for qualifying 8 antihypertensive drugs (AHDs) and 4
active metabolites was developed and validated using ultra high-
performance liquid chromatography-tandem mass spectrometry
(UHPLC-MS/MS).
Method: The DBS assay was validated analytically and clinically,
in accordance with FDA requirements. Analytical validation was
accomplished using UHPLC-MS/MS. For clinical validation, paired
peak and trough levels of DBS and plasma samples were simulta-
neously collected and comparatively analyzed using Deming
regression and Bland–Altman analyses. All concentrations below
the set lower limit were excluded. Deming regression analysis was
used to predict comparison bias between the collected plasma and
DBS samples, with DBS concentrations corrected accordingly.
Results: The UHPLC-MS/MS method for simultaneously measur-
ing 8 AHDs and their metabolites in DBS, was successfully
validated. With Deming regression no bias was observed in N = 1;
constant bias was seen in N = 6 and proportional bias in N = 11 of
the AHDs and metabolites. After correction for bias, only one metab-
olite (canrenone) met the 20% acceptance limit for quantification,
after Bland–Altman analyses. In addition, amlodipine, valsartan, and
[enalaprilate] met the 25% acceptance limit.
Conclusions: A novel DBS assay for simultaneously qualifying
and quantifying 8 AHDs and their metabolites, has been successfully
developed and validated. The DBS assay is therefore a suitable
method to detect drug nonadherence. However, with the exception of
canrenone, the interchangeable use of plasma and DBS sampling to
interpret drug quantities should be avoided.
Key Words: hypertension, clinical validation, drug monitoring,
chromatography, dried blood spot
(Ther Drug Monit 2020;42:460–467)
BACKGROUND
Hypertension is associated with increased risks of
cardiovascular events and end-organ damage.1,2 The use of
antihypertensive therapy to decrease blood pressure (BP) re-
duces stroke rates in as high as 30% of the respective patient
population.3 Antihypertensive drugs (AHDs) are an effective
hypertension therapy. However, nonadherence to antihyper-
tensive medication is one of the most common causes of
uncontrolled BP, hence the incorrect label “resistant hyper-
tension” in as high as 50% of the respective patient popula-
tion.4,5 Ultra high-performance liquid chromatography-
tandem mass spectrometry (UHPLC-MS/MS) is a reliable
method for measuring plasma AHD concentrations.6–8 How-
ever, its use is hampered by logistic challenges and its vul-
nerability to bias, attributable to white-coat adherence. The
dried blood spot (DBS) method is a more convenient and
patient-friendly technique for drug concentration measure-
ments. DBS can be performed by a simple finger prick,
enabling immediate sampling (in the general practitioner’s
office) when nonadherence is suspected, minimizing the risk
of white-coat adherence.9–11 However, minute differences
exist between DBS and plasma samples, and should be taken
into account when using this method. First, whole blood as
opposed to plasma, is used for the DBS assay, and is bene-
ficial to drugs that adhere to red blood cells, which normally
have lower plasma concentrations. Furthermore, because only
a drop of blood is sampled, the blood viscosity, and thereby
hematocrit, influences the quantity used for measurements.
More so, the shape of the drop is important for obtaining
reliable results during drug concentration measurements. It
was therefore necessary to validate this method extensively,
to observe for the similarities/equality in drug concentrations,
compared with plasma-only measurements. Although the
DBS method has been used to accurately measure immuno-
suppressive and antipsychotic drug concentrations,12–14 it has
Received for publication April 18, 2019; accepted August 1, 2019.
From the *Departments of Hospital Pharmacy; †Internal Medicine; and ‡Car-
diology, Erasmus MC, University Medical Center, Rotterdam, the Nether-
lands.
Supported by an Erasmus Medical Centre Mrace efficiency grant (2014-
14204).
L. E. J. Peeters and L. Feyz Contributed equally.
T. van Gelder has received grant support and lecture fees from Chiesi
Pharmaceuticals and Astellas Pharma, and consulting fees from Roche
Diagnostics, Vitaeris, Astellas, and Novartis. The remaining authors
declare no conflict of interest.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF
versions of this article on the journal’s Web site (www.drug-monitoring.
com).
Correspondence: Laura E. J. Peeters, MSc, Department of Hospital Pharmacy
and Department of Internal Medicine, Erasmus MC, Erasmus University
Medical Center, P.O. Box 2040, Na-222, 3000 CA Rotterdam, The
Netherlands (e-mail: l.e.j.peeters@erasmusmc.nl).
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
460 Ther Drug Monit  Volume 42, Number 3, June 2020
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
not been validated for AHD measurements.15–17 In this study,
we developed (following analytical validation) and clinically
validated a DBS method for 8 commonly used AHDs from
the 4 most frequently prescribed drug classes, by qualifying
and quantifying the AHD and active metabolite (displayed
within [brackets]) concentrations, using UHPLC-MS/MS.
Validation of the DBS-assay will give clinicians a reliable
and valuable new tool to address nonadherence in patients
with hypertension, which will benefit the patients by prevent-
ing cardiovascular events.
MATERIALS AND METHODS
Analytical Validation of the DBS Method to
Determine Reliability
Method Development
A sensitive UHPLC-MS/MS (Thermo Scientific, Wal-
tham, MA) assay was developed for the quantification of 8
AHDs and [their metabolites] in DBS. These include
angiotensin converting enzyme inhibitors; enalapril [enalap-
rilate] and perindopril [perindoprilate], angiotensin II receptor
blockers (ARB); losartan [losartan carboxylic acid (ca)] and
valsartan, diuretics; hydrochlorothiazide and spironolactone
[canrenone], and calcium channel blockers; amlodipine and
nifedipine. The UHPLC setup consisted of a Dionex Ultimate
system connected to a TSQ Vantage MS with a triple
quadrupole and heated electrospray ionization probe. Plasma
and DBS samples were prepared (plasma only) and analyzed
(plasma and DBS) as previously described.7 For DBS sam-
pling, filter papers (Whatman protein saver 903 card, Cardiff,
United Kingdom) were used, and one blood spot contained
one drop of whole blood. Using a manual disk puncher, a 6-
mm diameter sample was punched out of the blood spot.
Enalaprile-d5-maleate dissolved in a mixture of acetonitrile
and methanol (1:1), was used as internal standard, and added
to 7 AHD samples. For hydrochlorothiazide, an internal stan-
dard of hydrochlorothiazide-13CD2 was used. Thereafter,
samples were sonicated, centrifuged, and diluted with eluent.7
DBS assay validation was performed following the
FDA/EMA guidelines on bioanalytical method valida-
tion,18,19 and the concept guidelines of the alternative sam-
pling committee of the International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
(IATDCMT), and as previously described.12,20,21
Hematocrit
To investigate the influence of blood viscosity on
different AHD concentrations, blood with different hemato-
crit levels (0.3, 0.35, 0.4, and 0.45 L/L) was administered to
increasing AHD concentrations on DBS.22,23 Samples were
measured using the UHPLC-MS/MS method, as previously
described.7
Stability
The DBS samples were analyzed in batches. Although
studies indicate the relative stability of these drugs in
DBS,20,24–26 we studied AHD stability in our samples. Hence,
quality control (QC) samples (QC low, medium, and high)
were used, and then stored in a desiccator for 11 and 26 days
after sampling, at room temperature. The 11-day storage
period was considered clinically acceptable. Sample concen-
trations were comparable to those mentioned on Supplemen-
tal Digital Content 1 (see Table 1, http://links.lww.com/
TDM/A375). Measurements were done in 2-fold. Based on
the guidelines of the alternative sampling committee of
IATDCMT, a 615% degradation in the nominal value was
considered acceptable.27
The Clinical Validation Method: DBS
Concentrations versus Plasma Concentrations
Patients
Samples were collected between October 2016 and July
2018. A total of 135 patients were included, aiming for 40
paired samples/drug to validate the DBS method and ensure
statistical test validity, when comparing DBS and plasma
AHD/[metabolite] concentrations.24 Patients were selected
from the outpatient clinic (internal medicine, cardiology,
and nephrology) at the Erasmus Medical Center, Rotterdam,
The Netherlands.
As inclusion criteria, the automated BP measurement
(ABPM) (Datascope Accutor Plus, Paramus, NJ) or office BP
had to be ,135/85 mm Hg, to optimize the chances of sam-
pling an adherent patient, and the use of $2 AHDs for which
the DBS method had been developed. All available drug
dosages were exploited, in a bid to test and increase their
usability in clinical practice. Exclusion criteria included the
inability to provide written informed consent and proven non-
adherence, after sampling and inclusion; based on nonmea-
surable drug concentrations derived from plasma and DBS
samples when a peak drug level was expected. This study
was approved by the medical ethical committee of the Eras-
mus Medical Centre, Rotterdam, The Netherlands (MEC-
2016-162).
DBS and Plasma Sampling
DBS samples were obtained using the finger prick
method, following predetermined instructions; washing
hands, finger massage before and after puncture, and
sampling without card contact. The spots were allowed to
dry for at least 20 minutes, and the cards folded to keep the
blood spots away from light, to prevent the degradation of the
photo labile compounds amlodipine and nifedipine.28 The
DBS cards were then stored at room temperature in plastic
zipper bags containing silica desiccant, transported to the
laboratory, and placed in a desiccator until further analyses.
Venous whole blood samples were collected in ethylenedia-
minetetraacetic acid tubes during a regular venipuncture, pref-
erably obtained within the hour before or after DBS sampling.
For study purposes, an extra tube of blood was drawn (asides
that requested by the physician), sent to the pharmacy labo-
ratory, centrifuged, and the resulting plasma stored at 2808C
until analyses.
For each AHD, 2 hospital visits were required, because
the trough and peak levels of the same patient were measured
to validate the entire potential drug concentration range.24,29
The first visit, where BP was measured using ABPM, was
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planned in the morning to ensure drug levels were measured
approximately 1–7 hours after AHD intake (peak levels).
During the second visit (approximately 2 weeks later), veni-
puncture and DBS were performed to measure trough levels.
Here, patients were asked to delay their AHD intake until
after the appointment, to maximize trough levels at an interval
of $20 hours after intake. After attaining 20 samples (peak
and trough levels from 10 patients) per drug, the peak levels
for the remaining samples were then measured, as required for
validation. This adaptation improved the convenience of
study participation, as only 1 visit to the hospital was
required. Furthermore, it limited the number of negative val-
ues (trough levels .24 hours after the last intake were not
observed). Additional trough levels were obtained solely from
patients who accidently failed to self-medicate on the day of
measurement. Patients were allowed to participate more than
once.
Data Analysis
Analytical Validation
To determine DBS method reliability, the following
quantification limits were calculated, following the FDA/
EMA guidelines on bioanalytical method validation18,19: lin-
earity (by means of a calibration curve), limits of quantifica-
tion, intraday and interday accuracy, precision, and stability.
Matrix effects were measured as a whole, as opposed to indi-
vidually, because different matrices were used for subsequent
days. Reproducibility data were then used to determine any
matrix effects.
Clinical Validation
To compare quantitative data from DBS and plasma
samples, all samples below the lower limit of quantification
(LLOQ) were discarded. Outliers were determined using
boxplot analyses, because samples with extreme values were
excluded in further analyses. Deming regression analyses
were then performed to assess any constant and/or pro-
portional bias between plasma and DBS AHD/[metabolite]
measurements.12 A proportional bias was obtained if the 95%
confidence interval (95%-CI) of the regression line slope did
not contain 1. When the 95% CI of the regression line inter-
cept did not contain 0, the data were considered to have
a constant bias. These results were used to calculate the “esti-
mated plasma concentration.”30 The following formula was
used, and adjusted with respect to constant and/or propor-
tional bias: Estimated plasma concentration = (DBS concen-
tration 2 intercept of Deming regression line)/slope of
Deming regression line.
Using a Bland–Altman plot, the plasma AHD/
[metabolite] concentration measured from venipuncture sam-
ples was compared with the “estimated plasma concentration”
derived from DBS samples.24,31 According to the European
Guidelines on Bioanalytical Method Validation, $67% of the
measurements per drug should be within 20% of the mean of
the differences between the both methods.18
This difference was adopted as the acceptance limit,
although alterations could be made, based on clinical
relevance.12,32 Previous work showed that a within 25%
difference is also acceptable in AHDs, owing to their wide
therapeutic range.16 More so, to determine the suitability of
the DBS method in clinical practice, the number of DBS false
negatives, compared with those of plasma, were calculated.
Here, all samples were included independent of their LLOQ.
Analyses were performed using the IBM SPSS statistics
v24.0 software for Windows (IBM, Armonk, NY) and
GraphPad Prism 5 software (GraphPad Software, La Jolla,
CA).
RESULTS
Analytical Validation of the Method
A summary of the quantification limits is presented on
Supplemental Digital Content 1 (see Tables 1–3, http://
links.lww.com/TDM/A375). The lower limit of detection
(LLOD) and LLOQ for all drugs measured with DBS were
determined during analytical validation. For most analytes,
the lowest QC was higher, compared with the lowest mea-
sured DBS concentration. Hence, almost all low QCs failed to
meet the requirements. Therefore, the LLOQ was raised (in
comparison with the plasma method) to an acceptable value,
in accordance with the QCs.
Hematocrit
No differences were observed in AHD concentrations,
despite increasing hematocrit quantities. Therefore, no cor-
rection was required for measured DBS AHD/[metabolite]
concentrations, regarding hematocrit.
Stability
DBS cards with low, middle, and high concentrations
of the 8 AHDs and their metabolites were prepared on
different dates, and assessed for stability (see Table 4, Sup-
plemental Digital Content 1, http://links.lww.com/TDM/
A375). Amlodipine, losartan, [losartan-ca], [perindoprilate],
and enalapril, at all concentrations, showed no relevant differ-
ences in almost all QCs, after 11 and 26 days (,15% from the
nominal value). [Canrenone] displayed a difference in QC
low and medium after 11 and 26 days, which exceeded the
acceptance limit. Although valsartan and spironolactone
showed no relevant differences at low and median concen-
trations, their QC high values were above the acceptance limit
after 11 and 26 days. Nifedipine stability data showed .20%
degradation at medium and high concentrations. Hydrochlo-
rothiazide and [enalaprilate] proved unstable at different con-
centrations at both time points.
Clinical Validation of the DBS Method
Sampling
A total of 195 samples were obtained from 135 unique
patients. Patients (N = 3) were excluded when negative
plasma and DBS analyses were found in peak drug levels,
an indication of total or partial nonadherence.
Deming Regression Analyses
Before these analyses, samples below the LLOQ for
DBS and/or plasma were initially excluded (Table 1),
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followed by the exclusion of 2 [enalaprilate] sample outliers.
These outliers were seen in the venipuncture, and correspond-
ing DBS samples. The results of the Deming regression anal-
yses are presented in Table 1. Constant and proportional
biases were observed for the following 6 drugs of which [1
metabolite]: hydrochlorothiazide, losartan, nifedipine, peri-
ndopril, [perindoprilate], and spironolactone. Proportional
bias was observed for the following 5 drugs of which [3
metabolites]: amlodipine, [canrenone], [enalaprilate], valsar-
tan, and [losartan-ca] (see Fig. 1A1–3, Supplemental Digital
Content 1, http://links.lww.com/TDM/A375).
Bland–Altman Analyses
Results of the proportion within the 20% and 25%
range calculated using Bland–Altman analyses are presented
in Table 2. Only [canrenone] met the 20% acceptance limit
(Fig. 1A). For the 25% acceptance limit, additional AHDs;
amlodipine, valsartan, and one metabolite; [enalaprilate], met
the criteria. Moreover, the metabolites showed a better
agreement, compared with their respective parent drugs
(appendix; enalapril versus [enalaprilate], Fig. 1B versus C).
DBS False Negatives
False negatives for DBS compared with plasma are
displayed in Supplemental Digital Content 1 (see Table 5,
http://links.lww.com/TDM/A375). Overall, most negative
values were observed for the parent drugs: enalapril (5.2%),
losartan (4.8%), perindopril (4.9%), and spironolactone
(20.9%). Amlodipine, nifedipine, and [enalaprilate] only
had a single false negative, whereas valsartan, [canrenone],
and [losartan-ca] had no false negatives. Nevertheless, hydro-
chlorothiazide and [perindoprilate] had more false negatives
for DBS (9.4% and 9.8%, respectively), compared with other
measured drugs. These false negatives were found in random
samples, independent of drug dosage.
DISCUSSION
In this study, a clinically convenient DBS method for
qualifying and quantifying 8 AHDs and 4 metabolites from
the most frequently prescribed drug classes, was validated
using UHPLC-MS/MS. To the best of our knowledge, this is
the first study that compared AHDs in DBS and plasma in an
extensive number of samples from actual patients, instead of
spiked plasma samples. A good agreement was observed with
Deming regression analyses, after correction for outliers and
bias. Based on Bland–Altman analyses, only [canrenone] met
the 20% acceptance limits, implying that DBS and plasma
sampling could be used interchangeably when quantifying
[canrenone]. Also, the 25% acceptance limit was met by
valsartan, amlodipine, and [enalaprilate].
Analytical Validation
DBS is a reliable method for qualifying and quantifying
8 AHDs and 4 of their metabolites. However, the LLOD and
LLOQ were higher in DBS, compared to plasma (see Table
3, Supplemental Digital Content 1, http://links.lww.com/
TDM/A375). This was mainly due to the deviation in the
lowest QC of most drugs, during analytical validation. If
TABLE 1. Results of Deming Regression Analyses After Correction With the Conversion Formula for the Comparison of Plasma and
Estimated Plasma Concentrations (Derived From DBS)
Analyte N*
N £ LLOQ
DBS
N £ LLOQ
Veni Conversion Formula Slope
95% Confidence
Interval
Y-
Intercept
95% Confidence
Interval
Amlodipine 57 7 4 EPC = DBS · (1/slope) 1.443 1.258 to 1.628 2.537 20.990 to 6.606
Enalapril 25 12 7 No bias 0.960 0.737 to 1.182 6.272 23.901 to 16.450
Enalaprilate 27† 9 0 EPC = DBS · (1/slope) 0.416 0.349 to 0.484 4.348 22.822 to 11.520
Hydrochlorothiazide 42 26 42 EPC = ((DBS-intercept) ·
(1/slope))
3.540 2.225 to 4.856 2105.900 2276.600 to
64.680
Losartan 24 18 10 EPC = ((DBS-intercept) ·
(1/slope))
0.359 0.289 to 0.428 29.660 3.226 to 56.100
Losartan-ca 24 18 0 EPC = DBS · (1/slope) 0.506 0.330 to 0.682 5.337 286.460 to
97.140
Nifedipine 15 25 4 EPC = ((DBS- intercept)
· (1/slope))
0.622 0.330 to 0.915 29.250 10.580 to 47.910
Perindopril 14 26 23 EPC = ((DBS- intercept)
· (1/slope))
0.745 0.623 to 0.866 5.782 2.360 to 9.204
Perindoprilate 19 22 1 EPC = ((DBS- intercept)
· (1/slope))
0.485 0.328 to 0.642 3.688 0.480 to 6.896
Spironolactone 9 30 18 EPC = ((DBS- intercept)
· (1/slope))
0.527 0.242 to 0.812 18.650 10.530 to 26.780
Canrenone 22 20 2 EPC = DBS · (1/slope) 0.876 0.764 to 0.988 6.748 27.330 to 20.840
Valsartan 42 0 0 EPC = DBS · (1/slope) 0.553 0.479 to 0.627 26.017 2211.200 to
199.100
*After exclusion of samples below the LLOQ of DBS and/or plasma.
†Enalaprilate numbers were decreased as a result of 2 outliers.
ca, carboxylic acid; EPC, estimated plasma concentrations; N, number of samples; Veni, sample collected by venipuncture.
Clinical Validation of DBS for Antihypertensive DrugsTher Drug Monit  Volume 42, Number 3, June 2020
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. 463
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
the DBS method is used for AHD quantification, accurate
measurement of trough levels could be a challenge.
Our stability data showed that spironolactone and
[canrenone] were close to the acceptance limit of a ,15%
degradation. This reduced stability was expected for spirono-
lactone, as shown by van der Nagel et al7 for plasma. [Can-
renone] exceeded the limits for stability in QC low and
medium after 11 and 26 days, contrasting an earlier study
by Suyagh et al33 showing its DBS stability for as long as
1 month postsampling. Also, [enalaprilate] and hydrochloro-
thiazide stability data were hard to interpret, because they
were stable at different concentrations and time points. Tech-
nical issues in sample collection, capable of influencing the
quality of the spot, might have influenced stability outcome.
Nifedipine was the only unstable AHD after 11 days. Gener-
ally, these inconsistencies can be attributed to the fact that
DBS sampling is more susceptible to interindividual variabil-
ity. Therefore, it is believed that most drugs are more stable
than observed, with the exception of nifedipine.
Clinical Validation
Clinical validation was necessary to determine whether
DBS and plasma can be interchangeably used to quantify
drugs. Here, the LLOQ is one of the most important
parameters. Quantitative measurement is only accurate above
the LLOQ. Therefore, only measurements above the LLOQ
should be used in clinical validation studies. Given the raise
in DBS LLOQ, more samples than expected had to be
excluded. Before sample measurements, approximately 40
samples per drug were collected to meet the guideline-based
clinical validation criteria. However, only 3 of the 8 drugs
measured in this study had the appropriate amount of samples
after excluding samples below the LLOQ, and outliers. For
nifedipine, perindopril, [perindoprilate], and spironolactone in
particular, the number of excluded samples was so high,
denting the results from the Bland–Altman plot. Spi-
ronolactone is rapidly converted to [canrenone] after intake,
a probable reason why only few samples of spironolactone
were above the LLOQ. Therefore, for better quantitative
value interpretation, it is necessary to include [canrenone]
when measuring spironolactone. Fortunately, [canrenone] had
more samples above LLOQ and could be used to determine
plasma concentration after spironolactone intake.
However, for enalapril, losartan, and [losartan-ca],
which failed to meet the Bland–Altman criteria and had
,40 working measurements, it is unlikely that adding sam-
ples will enable the attainment of the required acceptance
limits.
The number of measurable concentrations for hydro-
chlorothiazide was low in our study population, for DBS and
plasma, compared with the quantity of samples collected.
Approximately half of all samples were excluded, owing to
a relatively high LLOQ, established via analytical validation.
This is probably due to a rapid decrease in plasma concen-
trations, whereby hydrochlorothiazide levels are already
below the LLOQ at 12 hours after intake.34,35 UHPLC-MS/
MS optimization is therefore necessary for improving hydro-
chlorothiazide LLOQ. However, in clinical practice, hydro-
chlorothiazide is often administered as a combination tablet;
hence, the presence of other drugs can, in this case, be used as
indication of hydrochlorothiazide intake.
When comparing blood drug concentrations without
adjustment for bias, higher DBS concentrations, compared
with plasma, were found for amlodipine, hydrochlorothiazide,
nifedipine, and perindopril. Conversely, for [perindoprilate],
[enalaprilate], losartan, [losartan-ca], and valsartan, higher
plasma concentrations were observed. This was independent
of the drugs’ protein binding or lipophilicity properties. How-
ever, the higher drug concentrations in whole blood have
been attributed to strong adhesion to red blood cells.36,37 It
is unclear whether these findings are related to the outcomes
of the Bland–Altman analyses.
The Deming regression analyses of losartan and
perindopril showed a great variation between plasma and
TABLE 2. Results of Bland–Altman Analyses of Plasma Versus Estimated Plasma Concentrations (Derived From DBS)
Analyte N* Mean Bias 95% Limits of Agreement D Within 20% of Average (%) D Within 25% of Average (%)
Amlodipine 57 1.76 26.36 to 9.87 57.9 71.9‡
Enalapril 25 5.17 230.13 to 40.48 36.0 44.0
Enalaprilate 27† 10.45 232.41 to 53.32 66.7 77.8‡
Hydrochlorothiazide 42 20.03 2113.58 to 113.51 45.2 52.4
Losartan 24 20.01 2291.88 to 291.86 12.5 16.7
Losartan-ca 24 10.61 2435.21 to 456.43 41.7 45.8
Nifedipine 15 0.00 248.53 to 48.54 26.7 33.3
Perindopril 14 0.00 211.99 to 11.99 28.6 28.6
Perindoprilate 19 0.01 212.77 to 12.78 31.6 31.6
Spironolactone 9 35.39 14.82 to 55.96 33.3 33.3
Canrenone 22 7.69 224.44 to 39.82 77.3‡ 86.4‡
Valsartan 42 20.09 21457.49 to 1457.31 61.9 73.8‡
*After exclusion of samples below the LLOQ of DBS and/or plasma.
†Enalaprilate numbers were decreased as a result of 2 outliers.
‡Values in agreement of the acceptance limit of .67% of the samples within 20% or 25% difference of the mean.
ca, carboxylic acid.
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DBS at peak levels. The latter could be attributed to the fact
that not all plasma and DBS samples were taken simulta-
neously, but often 30–60 minutes apart. Losartan and peri-
ndopril peak concentrations have reportedly been attained an
hour after intake.38,39 [Losartan-ca] and [perindoprilate], the
active metabolites of their parent drugs, attain peak concen-
trations at 3–4 hours after drug intake.40,41 In this study,
sampling was often done between 1 and 5 hours after drug
intake, corresponding to the metabolite and parent drug peak
concentration times. At peak concentrations, steep slopes
exist, emphasizing the importance of time between sampling.
This is one possible explanation for not meeting the Bland–
Altman acceptance criteria.
Also, perindopril and [perindoprilate] DBS and plasma
values were much lower, compared with valsartan for
instance (highest concentration for [perindoprilate] vs. val-
sartan measured with DBS: 23.51 versus 3883.06 mcg/L).
This difference is mainly attributable to the settings of the
UHPLC-MS/MS method. As a result, deviations in [peri-
ndoprilate] plasma and DBS concentrations have a much
greater impact on the Bland–Altman outcomes.
False negatives can result in wrong assumptions
toward patient nonadherence. [Perindoprilate] had the
most false negatives, compared with other metabolites.
However, these results can be attributed to the sampling
time after drug intake. For instance, one sample was taken
,1 hour after drug intake, and another, 36 hours after
intake (trough sample). This explains why both samples
showed no [perindoprilate] for the DBS method. Wrong
patient information on the time of drug intake may have
also skewed results. Here, [perindopril] was totally absent
in the plasma and DBS sample, and low [perindoprilate]
concentrations were observed in the plasma samples.
These findings were in accordance with samples used for
trough level measurements, indicating that the information
given by the patients on time of drug intake was
FIGURE 1. Bland–Altman analyses of [canrenone]
(A), enalapril (B), and [enalaprilate] (C). The dotted
line in each graph depicts 20% acceptable bias when
comparing plasma and DBS measurements. Enalap-
rilate and canrenone are the active metabolites of
respectively enalapril and spironolactone and are
shown within brackets. EPC, Estimated plasma
concentrations.
Clinical Validation of DBS for Antihypertensive DrugsTher Drug Monit  Volume 42, Number 3, June 2020
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. 465
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
inaccurate. Other false negatives were mainly observed for
parent drugs, and were nullified by results from their cor-
responding metabolites. It is therefore very important for
any nonadherence detection method to include the parent
drug, and their metabolites.
Considerations when Using DBS
The main advantage DBS has above plasma measure-
ments is the ability of sampling to occur at the same time as
BP measurements, and at any given location, without the need
for an additional visit to a blood sampling facility. DBS
sampling is less invasive and less time-consuming for the
patient, compared with venipuncture. For the 8 AHDs
measured, the metabolites were more often detected, com-
pared with the parent drugs. Furthermore, for the AHDs with
the best correlation, such as [canrenone] and [enalaprilate],
DBS could also be useful for PK/pharmacodynamic (PD)
modeling, with more intense sampling. This could be
convenient for patients who have great variation in drug
concentrations when using the same dose, including the
elderly and female patients.42
Differences between DBS and plasma can be explained
from several angles; stability, DBS sampling method, and
blood spot quality,43 with the sampling method and blood
spot quality being of great importance. According to previous
studies, measuring a different spot on the same card, which
theoretically contains the same drug concentration, showed
a difference in mean, from 225% to almost 40%.43 This
could be attributed to different spot sizes, irregularities, spot
overlap, or multiple spots in one area. Some suboptimal spots
were also seen in our samples, particularly in the drug con-
centrations that deviated from the Bland–Altman acceptance
limits. It is therefore recommended to evaluate spot quality
before analyses, because not all blood spots are similar and/or
of good quality. This is also the most likely explanation for
the stability results observed in this study, during analytical
validation. Stability challenges were observed for nifedipine
when the drug was sampled with DBS, which may explain
why it failed to meet the acceptance limits for Bland–Altman
analyses.
Despite the possible stability and technical sampling
problems, all AHDs in DBS were measured, with some
agreement in the Bland–Altman analyses, when DBS and
plasma measurements were compared. This implies the effi-
ciency of DBS in determining nonadherence for all measured
AHDs over all available dosages, because it could measure
the presence of a drug with a high accuracy for as long as 24
hours after intake; the most important factor. This can pre-
serve a good patient–physician relationship, which is key to
properly discussing the outcome of the absence of drugs in
the blood. The use of DBS, and discussions on the outcome,
to improve nonadherence, is currently being studied in a large
multicenter trial called RHYME-RCT (NL6736). However, to
quantify drug concentrations, it is important to choose one of
the methods (DBS or plasma) and avoid interchanges. Also,
a more detailed analyses with respect to the quantitative val-
ues, may be considered in the future, to determine long-term
adherence.
CONCLUSIONS
DBS is a reliable and accurate method for measuring
AHDs, and is therefore applicable for nonadherence
assessment/detection. DBS sampling enables AHD quantifi-
cation. However, when measuring trough levels, venipuncture
is more accurate. In addition, DBS and plasma should not be
used interchangeably when quantifying AHDs, with the
exception for valsartan.
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